BMS-986435
- Generic Name
- BMS-986435
Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2025-03-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT06577259
- Locations
- πΊπΈ
Local Institution - 0001, San Antonio, Texas, United States
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT06476821
- Locations
- π¨π³
Local Institution - 0001, Xuhui District, Shanghai, China
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
- First Posted Date
- 2023-11-08
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 198
- Registration Number
- NCT06122779
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈLocal Institution - 0096, Lakewood, Colorado, United States
πΊπΈLocal Institution - 0077, Jacksonville, Florida, United States
A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT05686096
- Locations
- πΊπΈ
Local Institution - 0001, Madison, Wisconsin, United States
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT05556343
- Locations
- πΊπΈ
Local Institution - 0014, Los Angeles, California, United States
πΊπΈLocal Institution - 0016, San Francisco, California, United States
πΊπΈLocal Institution - 0026, La Jolla, California, United States
A Study to Evaluate the Safety, Tolerability, and Drug Levels of MYK-224 Administered in Single and Multiple Doses in Healthy Adult Japanese Participants
- First Posted Date
- 2022-06-06
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT05405543
- Locations
- πΊπΈ
Local Institution - 0001, Anaheim, California, United States
A Study to Assess the Drug Interaction Between MYK-224 and Itraconazole and Verapamil in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 45
- Registration Number
- NCT05304533
- Locations
- πΊπΈ
Local Institution - 0001, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.